MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid and ...

North Lauderdale resident Ethel Rentas, BSN, R.N., CCRN, a nurse at Holy Cross Health, was recognized as the hospital's ...

This blog post explores the factors contributing to air pollution and introduces two instruments for continuous ambient air ...

The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple ...

Microdosing, or low-dose treatment of psychedelics such as lysergic acid diethylamide (LSD), has gained popularity in recent ...

Our interdisciplinary school is leading scientific exploration and engineering expertise in sustainability solutions, biomedical innovation and advanced materials. We address crucial issues like ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...

Sarepta will update Elevidys’ label after a patient died following treatment; the FDA issues flu vaccine recommendations ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

In this edition of “Rising High,” The Fly conducted an exclusive interview with Jared Stanley, Chief Executive Officer, and Joel Stanley, ...

The global next-generation titrator market is on an impressive growth trajectory, with market size expected to surge from USD 3,820.6 million in 2024 to USD 7,171.9 million by 2034. This expansion, at ...